PMVP

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is a precision oncology company founded in 2013 and headquartered in Cranbury, New Jersey. Originally incorporated as PJ Pharmaceuticals, Inc., the company changed its name to PMV Pharmaceuticals in July 2013 and went public in September 2020. PMV focuses on developing small molecule therapies that target specific mutations in the p53 protein, which is often called the "guardian of the genome" due to its critical role in preventing cancer development. The company operates in the highly specialized field of precision oncology, where treatments are designed to target specific genetic mutations found in cancer patients.